Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 05/28/2026 at 16:00, 28 days 4 hours ago

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Jaguar Health's crofelemer, an FDA-approved botanical drug derived from Croton lechleri tree, developed as first oral adjunctive therapy for Intestinal Failure (IF) from MVID and SBS, highlighting unique botanical drug platform and indigenous collaboration

Crofelemer Jaguar Health FDA-approved Botanical Drug Intestinal Failure
BRIEF

published on 05/27/2026 at 15:05, 29 days 5 hours ago

Jaguar Health Regains Nasdaq Compliance

Revenue Growth Financial Performance Jaguar Health Nasdaq Compliance Crofelemer Program
BRIEF

published on 05/27/2026 at 15:05, 29 days 5 hours ago

Jaguar Health retrouve sa conformité au Nasdaq

Performance Financière Jaguar Health Croissance Des Revenus Conformité NASDAQ Programme Crofelemer
PRESS RELEASE

published on 05/27/2026 at 15:00, 29 days 5 hours ago

Jaguar Health Compliant with Nasdaq Bid Price Rule
Jaguar Health, Inc. (NASDAQ:JAGX) regains compliance with Nasdaq Listing Rule 5550(a)(2) as securities continue to be listed and traded on Nasdaq, with significant revenue growth reported

Revenue Growth Compliance Nasdaq Jaguar Health Nasdaq Listing Rule
BRIEF

published on 05/20/2026 at 22:45, 1 month 4 days ago

Jaguar Health Announces Strong Financial Growth in Q1 2026

Licensing Agreement Financial Growth Net Revenue Crofelemer Development Operational Income
BRIEF

published on 05/20/2026 at 22:45, 1 month 4 days ago

Jaguar Health annonce une forte croissance financière au premier trimestre 2026

Croissance Financière Revenu Net Contrat De Licence Développement Crofelemer Revenu D'exploitation
PRESS RELEASE

published on 05/20/2026 at 22:40, 1 month 4 days ago

Jaguar Health Reports First Quarter 2026 Financials
Jaguar Health, Inc. reports significant revenue increase driven by license agreements for Mytesi® and Canalevia®-CA1, focuses on crofelemer development for rare intestinal indications. Upcoming presentations at ESPGHAN Meeting. Info on investor webcast and CEO's virtual presentation

Revenue Increase Investor Webcast Jaguar Health Inc. Crofelemer Development License Agreements
BRIEF

published on 05/19/2026 at 15:05, 1 month 6 days ago

Jaguar Health fait progresser l'essai clinique pour le traitement de la MVID

Crofelemer Essai Clinique Traitement MVID Soutien Parentéral Santé Pédiatrique
BRIEF

published on 05/19/2026 at 15:05, 1 month 6 days ago

Jaguar Health Advances Clinical Trial for MVID Treatment

Crofelemer Clinical Trial MVID Treatment Parenteral Support Pediatric Health
PRESS RELEASE

published on 05/19/2026 at 15:00, 1 month 6 days ago

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
First MVID patient enters active treatment extension phase with liquid crofelemer as adjunctive therapy. Jaguar Health focuses on rare pediatric disease treatment

Crofelemer Jaguar Health Treatment MVID Pediatric

Published on 06/25/2026 at 15:30, 4 hours 44 minutes ago

Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/25/2026 at 15:00, 5 hours 14 minutes ago

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
Published on 06/25/2026 at 14:30, 5 hours 44 minutes ago

Unusual Machines Expands Orlando Manufacturing Footprint to Support Battery Operations
Published on 06/25/2026 at 14:01, 6 hours 13 minutes ago

Worksport (NASDAQ:WKSP) Regains $1 Bid Price Requirement, Announces CEO Town Hall, Highlights Multiple Recent Growth Drivers in CEO Letter
Published on 06/25/2026 at 14:00, 6 hours 14 minutes ago

Horizon Aircraft's Leadership Team to Participate at Farnborough International Airshow 2026

View all ACCESSWIRE

Published on 06/25/2026 at 19:00, 1 hour 13 minutes ago

EQS-Adhoc: H&R GmbH & Co. KGaA resolves to prepare for the transition from the regulated market (Prime Standard) to the Scale segment of the Frankfurt Stock Exchange
Published on 06/25/2026 at 18:59, 1 hour 14 minutes ago

OHB Digital Connect completes upgrade of military ground stations
Published on 06/25/2026 at 18:40, 1 hour 33 minutes ago

Texas Cardiac Arrhythmia Institute at St. David's Medical Center hosts international conference on complex cardiac arrhythmias
Published on 06/25/2026 at 18:30, 1 hour 44 minutes ago

Delisting of Northern Data AG Shares - Munich Stock Exchange Decides on the Timeline
Published on 06/25/2026 at 18:00, 2 hours 14 minutes ago

EUROPLASMA: Projet de cession des activités de défense : poursuite des discussions

View all EQS

Published on 06/25/2026 at 18:45, 1 hour 28 minutes ago

Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 1 hour 44 minutes ago

Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 2 hours 24 minutes ago

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 06/25/2026 at 17:50, 2 hours 24 minutes ago

DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 06/25/2026 at 15:58, 4 hours 15 minutes ago

260625 BENETEAU Transactions sur actions propres

View all LES ECHOS COMFI WIRE

News